Verily links with Janssen for at-home COVID-19 immune system study
Excerpt from the Article:
Verily is teaming up with Johnson & Johnson’s Janssen division to observe the body’s earliest immune responses to a coronavir12us infection, with people participating in the research from within their own homes.
The study will be launched through Verily’s Project Baseline testing program and aims to collect biological information and real-world data in the weeks immediately after a person tests positive for COVID-19.
The goal is to identify early warning biomarkers that could help guide healthcare providers through future treatments as well as potentially predict whether an individual’s case may turn severe.
“Acute respiratory distress syndrome caused by SARS-COV-2 and other viral and bacterial pathogens carries with it a high mortality rate, and more than 2.2 million people will suffer each year as a result,” said James Merson, Ph.D., Janssen’s global head of infectious disease R&D.
“Since immune response patterns observed in COVID-19 patients are similar to those caused by other respiratory pathogens, it is our hope to apply the findings from this study beyond COVID-19 to other illnesses that carry a high patient burden,” Merson said.
Click the button below to read the entire Article:
Discover What Sets TrialStat Apart From Ordinary Data Management
Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?